KM-501 / Sihuan Pharmaceutical - LARVOL DELTA

Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China (PRNewswire) - "Innovent Biologics...and Xuanzhu Biopharma, today announce that they entered into a clinical trial collaboration and supply agreement for the combination therapies of sintilimab injection (brand name: TYVYT) with KM-501, a novel HER-2 bispecific ADC, as potential treatment options for advanced solid tumors in China. Under the agreement, Innovent will supply sintilimab for the collaborated clinical trial. Xuanzhu Biopharma will conduct a Phase 1b clinical study to evaluate the anti-tumor activity and safety of the combination therapy of sintilimab with KM-501 in Chinese patients with advanced solid tumors."

Licensing / partnership • New P1 trial • Solid Tumor